Business Context and Reporting Period
This Form 8-K Current Report was filed by Milestone Pharmaceuticals Inc. on July 22, 2020. The Company is an emerging growth company incorporated in Québec, Canada, with its principal executive offices in Montréal. The report primarily addresses a material definitive agreement entered into on July 22, 2020, and other events occurring on July 23, 2020.
Key Financial Metrics
The filing details a private placement transaction rather than periodic financial results. Key metrics related to this transaction include:
- Gross Proceeds: Approximately $25 million expected from the private placement.
- Securities Issued: Pre-funded warrants to purchase up to 6,655,131 common shares.
- Purchase Price: $3.7465 per pre-funded warrant.
- Exercise Price: Initial exercise price of $0.01 per share.
- Expiration: No expiration date.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a current report on specific events, not a quarterly or annual financial statement.
Material Changes
The primary material change is the entry into a securities purchase agreement with affiliates of RTW Investments, LP, an existing shareholder. This transaction represents a significant capital raise intended to fund operations and clinical development. The closing of the transaction is expected on or about July 24, 2020, subject to customary conditions.
Guidance, Outlook, and Other Events
On July 23, 2020, the Company issued press releases regarding:
- Regulatory Guidance: Updated clinical development plan for its pivotal program with etripamil in paroxysmal supraventricular tachycardia (PSVT).
- Conference Call: A call was scheduled for July 23, 2020, at 8:30 a.m. ET to discuss the regulatory guidance and the private placement.
The Company agreed to file a registration statement within 30 days to register for resale the shares underlying the pre-funded warrants. The filing does not contain specific forward-looking financial guidance or detailed risk factors beyond standard transaction terms.
Investor Verification Checklist
- Verify the closing of the private placement and the receipt of the approximately $25 million in gross proceeds.
- Review the detailed terms of the Securities Purchase Agreement (Exhibit 10.1) and Form of Pre-Funded Warrant (Exhibit 4.1).
- Confirm the regulatory guidance received for the etripamil PSVT program as detailed in the July 23, 2020 press release (Exhibit 99.1).
- Monitor the filing of the registration statement for the resale of shares underlying the pre-funded warrants within the 30-day window.